Showing results (1-10 of 219) with videos related to
Sort By:
Pageof 22
Cell|April 23, 2016
Partnering with Big Pharma-What Academics Need to KnowStuart A Lipton, Christer NordstedtNature Reviews. Drug Discovery|January 21, 2006
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyondStuart A LiptonCurrent Opinion in Pharmacology|July 23, 2022
Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathwaysStuart A LiptonFree Radical Biology & Medicine|October 15, 2022
Hidden networks of aberrant protein transnitrosylation contribute to synapse loss in Alzheimer's diseaseStuart A LiptonThe European Journal of Neuroscience|January 1, 1992
7-Chlorokynurenate Ameliorates Neuronal Injury Mediated by HIV Envelope Protein gp120 in Rodent Retinal CulturesStuart A. LiptonCurrent Alzheimer Research|June 25, 2005
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonismStuart A LiptonJournal of Alzheimer'S Disease : JAD|January 25, 2005
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disordersStuart A LiptonSurvey of Ophthalmology|July 11, 2003
Possible role for memantine in protecting retinal ganglion cells from glaucomatous damageStuart A LiptonCurrent Drug Targets|May 17, 2007
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylationStuart A LiptonNeurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2005
Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insultsStuart A LiptonPageof 22